Health Canada has granted a Notice of Compliance (NOC) for Saphnelo® (anifrolumab injection) for subcutaneous self-administration via a single-use autoinjector for adult patients with active, ...
ZURICH, Feb. 24, 2025 /PRNewswire/ -- Takeda (TSE: 4502) (NYSE: TAK) announced today that the EMA has approved an additional 2 mL pre-filled pen option for TAKHZYRO® (lanadelumab) for subcutaneous ...
OPDIVO is a prescription medicine used in combination with YERVOY as a first treatment to treat adults with cancer of the ...
This marks the approval of the first and only subcutaneous immune checkpoint inhibitor in Europe that can be administered by a health care provider in as little as one minute “We are honored to ...
ORLANDO, Fla.--(BUSINESS WIRE)-- Millennium: The Takeda Oncology Company today reported results from a randomized, international Phase III clinical trial comparing subcutaneous and intravenous ...
PD-1 inhibitors belong to a class of medications known as immune checkpoint inhibitors, which have become an important part of many modern cancer treatment plans. PD-1 inhibitors work by helping the ...
First biologic available in both subcutaneous (SC) and intravenous (IV) formulations for the treatment of rheumatoid arthritis Subcutaneous ORENCIA demonstrated similar efficacy (non-inferior for ...
In the new subcutaneous drug delivery landscape, the growing trend towards patient-friendly, at-home administration is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results